Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
57.17 USD | -0.47% | -0.61% | -27.60% |
May. 21 | News Highlights : Top Company News of the Day - Tuesday at 1 PM ET | DJ |
May. 21 | News Highlights : Top Company News of the Day - Tuesday at 11 AM ET | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Its low valuation, with P/E ratio at 9.9 and 8.45 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.33 times its sales.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.60% | 72.11B | B- | ||
+16.83% | 83.4B | C+ | ||
0.00% | 27.04B | C+ | ||
-12.01% | 16.96B | B | ||
+0.78% | 16.86B | A- | ||
+3.37% | 15.76B | A- | ||
+74.35% | 13.33B | C- | ||
+1.81% | 12.76B | B- | ||
+72.20% | 12.74B | C+ | ||
+1.50% | 12.32B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVS Stock
- Ratings CVS Health Corporation